A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

Conditions

• Nausea and Vomiting
• Obesity

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Accepted

Interventions

• Tradipitant — DRUG
  Oral Capsule
• Placebo — DRUG
  Oral Capsule

Study Details

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Key Dates

Start date

Mar 27, 2026

Status verified

Feb 2026

Primary completion

Dec 1, 2026

Completion

Dec 1, 2026

Study Design

Enrollment

280 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: Placebo Group
  Treatment with placebo BID for approximately 2 weeks
• Experimental: Tradipitant Group
  Treatment with tradipitant BID for approximately 2 weeks

Primary Outcome Measure

Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary. [ Time Frame: 1 week ]

Central Contacts

• Vanda Pharmaceuticals
  (202) 734-3400
  [email protected]

Locations (10)

Find similar trials in Los Angeles, CA

Related Studies

• Domperidone in Treating Patients With Gastrointestinal Disorders
  PHASE3 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.
  Recruiting · Columbia University · Boston, Massachusetts
• Inflammation, Diabetes, Ethnicity and Obesity Cohort
  Recruiting · University of California, San Francisco · San Francisco, California
• Circadian Misalignment and Energy Balance
  Recruiting · Columbia University · New York, New York